SCHEMBL5651691

SCHEMBL5651691

Cc1ccc(-c2ccc(C(=O)Nc3ccc4cc(CN5CCCCCC5)cnc4c3)cc2)cc1

nearest known ligand 0.98

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 20/20 0.98
HTR2C P28335 13/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648842 0.99 MCHR1 (1.00) MCHR1HTR2C
SCHEMBL5647747 0.92 MCHR1 (0.98) MCHR1HTR2C
SCHEMBL5647751 0.91 MCHR1 (0.98) MCHR1HTR2C
SCHEMBL5645431 0.91 MCHR1 (1.00) MCHR1HTR2C
SCHEMBL5647227 0.90 MCHR1 (0.98) MCHR1HTR2C
SCHEMBL5646061 0.90 MCHR1 (0.98) MCHR1HTR2C
SCHEMBL6490307 0.90 MCHR1 (0.98) MCHR1HTR2C
SCHEMBL5647090 0.90 MCHR1 (1.00) MCHR1HTR2C
SCHEMBL5645114 0.90 MCHR1 (0.98) MCHR1HTR2C
SCHEMBL5651597 0.89 MCHR1 (1.00) MCHR1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183415-B2 Quinoline compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-7183415-B2 Quinoline compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-7183415-B2 Quinoline compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050209213-A1 Quinoline compound TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-09-22 US disclosed
EP-1447402-A1 QUINOLINE COMPOUND Takeda Chemical Industries, Ltd. (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209213-A1 Quinoline compound MC1R, MC2R, TYR MCHR1 4/4885HTR2C 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.